

Claims

1-14. (Canceled)

15. (Currently Amended) A method for treating an SSSTR-associated disorder in a mammalian subject in need thereof, the method comprising:

administering to the subject a ~~composition~~ conjugate comprising:

(a) a somatostatin analog of the formula:

(A – B), which comprises (i)

~~wherein:~~

A, which is a peptide chain or a single amino acid comprising one or more cysteine residues[.,.]; and (ii) B, which is a naturally occurring or synthetic somatostatin peptide, or fragment thereof, which binds to a somatostatin receptor; and

(b) ~~wherein~~ a therapeutic agent, which is bound to the somatostatin analog (A – B) via a thiol linkage to the one or more cysteine residues of (A) at an interior site(s);

whereby a SSSTR-associated disorder is treated.

16. (Original) The method of claim 15, wherein A comprises the peptide sequence of any one of SEQ ID NOs:1-3, or wherein A is a single cysteine residue.

17. (Original) The method of claim 15, wherein B comprises SEQ ID NO:4.

18. (Original) The method of claim 15, wherein the somatostatin analog comprises a peptide of any one of SEQ ID NOs:5-7.

19. (Original) The method of claim 15, wherein the therapeutic agent is selected from the group consisting of a radioisotope, a cytotoxin, an immunostimulatory agent, an anti-angiogenic agent, a therapeutic gene, and a chemotherapeutic agent.

20. (Original) The method of claim 15, wherein the SSTR-associated disorder is cancer.